Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Other 1Gastrointestinal 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Rectal Neoplasms 1Anus Neoplasms 1

Interventions

fludarabine 3Vaccines 3Radiotherapy 3Papillomavirus Vaccines 3Nivolumab 3Cyclophosphamide 3pembrolizumab 2entinostat 2aldesleukin 2aflibercept 2Trastuzumab 2Surveys and Questionnaires 2Specimen Handling 2Radiation 2Observation 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2Adoptive Transfer 2trastuzumab deruxtecan 1tivozanib 1tipifarnib 1rocakinogene sifuplasmid 1oncogene protein E7, Human papillomavirus type 16 1nanocis 1durvalumab 1bintrafusp alfa protein, human 1atezolizumab 1Watchful Waiting 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × Dehydroepiandrosterone × Gastrointestinal × Clear all
NCT07407647 2026-04-21

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
25 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Rectal Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡